JP2013531238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531238A5 JP2013531238A5 JP2013515841A JP2013515841A JP2013531238A5 JP 2013531238 A5 JP2013531238 A5 JP 2013531238A5 JP 2013515841 A JP2013515841 A JP 2013515841A JP 2013515841 A JP2013515841 A JP 2013515841A JP 2013531238 A5 JP2013531238 A5 JP 2013531238A5
- Authority
- JP
- Japan
- Prior art keywords
- cer
- lipid
- total
- laccer
- apolipoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BPLYVSYSBPLDOA-WVILEFPPSA-N N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC BPLYVSYSBPLDOA-WVILEFPPSA-N 0.000 claims 47
- 208000037998 chronic venous disease Diseases 0.000 claims 35
- 150000002632 lipids Chemical class 0.000 claims 35
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 27
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 27
- FGJIXPPBZNPEHW-CRMMDXJYSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-eicosanoylsphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 FGJIXPPBZNPEHW-CRMMDXJYSA-N 0.000 claims 27
- 239000000523 sample Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 21
- SXPRAKSDHOEHIG-ZESVVUHVSA-N N-docosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC SXPRAKSDHOEHIG-ZESVVUHVSA-N 0.000 claims 20
- VODZWWMEJITOND-NXCSZAMKSA-N N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-NXCSZAMKSA-N 0.000 claims 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 18
- XWBWIAOWSABHFI-NUKVNZTCSA-N N-icosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC XWBWIAOWSABHFI-NUKVNZTCSA-N 0.000 claims 14
- 206010000891 acute myocardial infarction Diseases 0.000 claims 14
- 101710095342 Apolipoprotein B Proteins 0.000 claims 13
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 13
- QYWVASPEUXEHSY-NNRNTGNWSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-(docosanoyl)sphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QYWVASPEUXEHSY-NNRNTGNWSA-N 0.000 claims 11
- 239000013068 control sample Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 235000012000 cholesterol Nutrition 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- KEPQASGDXIEOIL-UHFFFAOYSA-N (2S,3R)-N-(docosanoate)-1,3-dihydroxy-2-amino-octadeca-4-(E)-ene Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC KEPQASGDXIEOIL-UHFFFAOYSA-N 0.000 claims 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 7
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 7
- KEPQASGDXIEOIL-GLQCRSEXSA-N N-docosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC KEPQASGDXIEOIL-GLQCRSEXSA-N 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 108010023302 HDL Cholesterol Proteins 0.000 claims 4
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 4
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 4
- 108010028554 LDL Cholesterol Proteins 0.000 claims 4
- KDEYEEYMIPNKIJ-OGIIFMLESA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-tetracosanoylsphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KDEYEEYMIPNKIJ-OGIIFMLESA-N 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- MKOKWBRPIBQYJJ-WZBOJYASSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-[(15Z)-tetracosenoyl]sphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MKOKWBRPIBQYJJ-WZBOJYASSA-N 0.000 claims 3
- 239000013589 supplement Substances 0.000 claims 3
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims 2
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims 2
- 102000018616 Apolipoproteins B Human genes 0.000 claims 2
- 108010027006 Apolipoproteins B Proteins 0.000 claims 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229920001268 Cholestyramine Polymers 0.000 claims 1
- 229920002905 Colesevelam Polymers 0.000 claims 1
- 229920002911 Colestipol Polymers 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 1
- 101710105047 Lipoprotein B Proteins 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 claims 1
- 229950000285 anacetrapib Drugs 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 229960000516 bezafibrate Drugs 0.000 claims 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 229940096699 bile acid sequestrants Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229960001214 clofibrate Drugs 0.000 claims 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 1
- 229960001152 colesevelam Drugs 0.000 claims 1
- 229960002604 colestipol Drugs 0.000 claims 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 238000001506 fluorescence spectroscopy Methods 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960003627 gemfibrozil Drugs 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000005305 interferometry Methods 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 230000010287 polarization Effects 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- IMNTVVOUWFPRSB-JWQCQUIFSA-N sch-48461 Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(OC)=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 IMNTVVOUWFPRSB-JWQCQUIFSA-N 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 claims 1
- 229950004514 torcetrapib Drugs 0.000 claims 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10006399 | 2010-06-20 | ||
| EP10006399.9 | 2010-06-20 | ||
| US35667510P | 2010-06-21 | 2010-06-21 | |
| US61/356,675 | 2010-06-21 | ||
| PCT/EP2011/060253 WO2011161062A2 (en) | 2010-06-20 | 2011-06-20 | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017042837A Division JP6605521B2 (ja) | 2010-06-20 | 2017-03-07 | 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531238A JP2013531238A (ja) | 2013-08-01 |
| JP2013531238A5 true JP2013531238A5 (enExample) | 2015-02-12 |
| JP6262529B2 JP6262529B2 (ja) | 2018-01-17 |
Family
ID=44627661
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013515841A Active JP6262529B2 (ja) | 2010-06-20 | 2011-06-20 | 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー |
| JP2017042837A Active JP6605521B2 (ja) | 2010-06-20 | 2017-03-07 | 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017042837A Active JP6605521B2 (ja) | 2010-06-20 | 2017-03-07 | 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US9201080B2 (enExample) |
| EP (2) | EP3293522A3 (enExample) |
| JP (2) | JP6262529B2 (enExample) |
| CN (2) | CN103154742B (enExample) |
| CA (1) | CA2801459C (enExample) |
| WO (1) | WO2011161062A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| EP2592422A1 (en) * | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2667197B1 (en) * | 2012-05-25 | 2015-09-16 | Zora Biosciences OY | Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition |
| US20130312498A1 (en) * | 2012-05-25 | 2013-11-28 | Foundation For Health Improvement And Technology | Cardiovascular disease risk assessment and treatment by sterol and/or stanol markers |
| EP2965092A1 (en) * | 2013-03-08 | 2016-01-13 | Zora Biosciences OY | Non-high density lipoprotein derived cvd markers |
| CN104063570B (zh) * | 2013-03-20 | 2017-06-16 | 中国科学院大连化学物理研究所 | 一种脂质代谢网络动态研究的方法 |
| KR101594515B1 (ko) * | 2013-12-24 | 2016-02-16 | 연세대학교 산학협력단 | 혈장 대사체를 이용한 제2형 당뇨병 진단 키트 |
| BR112016023418A8 (pt) | 2014-04-10 | 2019-12-10 | MEP Equine Solutions LLC | método e kit para a quantificação de ovos de parasitas nas fezes |
| US9347960B2 (en) | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| CN108027354B (zh) * | 2015-08-20 | 2021-01-08 | 深圳华大生命科学研究院 | 冠心病的生物标志物 |
| US10184932B2 (en) | 2015-12-07 | 2019-01-22 | Zora Biosciences Oy | Use of ceramides and LPLs in diagnosing CVD |
| CN105628809B (zh) * | 2015-12-25 | 2018-04-03 | 中国药科大学 | 用于诊断区分冠状动脉粥样硬化和冠心病的代谢标志物 |
| CN105424841B (zh) * | 2015-12-25 | 2017-11-03 | 齐炼文 | 用于诊断冠状动脉粥样硬化的代谢标志物 |
| CN105486773A (zh) * | 2015-12-25 | 2016-04-13 | 齐炼文 | 用于诊断冠心病的代谢标志物 |
| CN105445408B (zh) * | 2016-01-25 | 2018-06-12 | 齐炼文 | 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物 |
| CN109870536B (zh) * | 2017-12-05 | 2021-08-10 | 中国科学院大连化学物理研究所 | 一种基于液相色谱-质谱联用的高覆盖脂质组学分析方法 |
| CN114062581A (zh) * | 2017-12-14 | 2022-02-18 | 江苏豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2020115288A1 (en) | 2018-12-06 | 2020-06-11 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| WO2022079704A1 (en) * | 2020-10-16 | 2022-04-21 | Indian Institute Of Science | A lipid based indicator for cardiovascular disorder |
| CN112147344B (zh) * | 2020-10-30 | 2021-07-13 | 河北医科大学第二医院 | 动脉粥样硬化性脑梗死的代谢标志物及其在诊疗中的应用 |
| CN112305124B (zh) * | 2020-10-30 | 2022-03-04 | 河北医科大学第二医院 | 一种生物标志物及其在疾病诊断中的应用 |
| CN112305119B (zh) * | 2020-10-30 | 2021-08-17 | 河北医科大学第二医院 | 动脉粥样硬化性脑梗死的生物标志物及其应用 |
| EP4043884A1 (en) * | 2021-02-10 | 2022-08-17 | Eberhard-Karls-Universität Tübingen | Medium-chain fatty acyls and phospholipids as biomarkers for cardiovascular diseases |
| CN113533754A (zh) * | 2021-07-12 | 2021-10-22 | 北京市心肺血管疾病研究所 | 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用 |
| CN114791459B (zh) * | 2022-03-29 | 2023-02-14 | 浙江苏可安药业有限公司 | 用于检测肺结核的血清代谢标志物及其试剂盒 |
| CN117589897A (zh) * | 2023-11-09 | 2024-02-23 | 首都医科大学附属北京朝阳医院 | 冠心病血清学预警生物标志物、检测试剂及试剂盒 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002514999A (ja) * | 1991-09-26 | 2002-05-21 | ヘム・ファーマスーティカル・コーポレーション | ｄｓＲＮＡを用いてＩＬ−１を中和する方法 |
| US6210976B1 (en) | 1997-06-10 | 2001-04-03 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| AU5610801A (en) | 2000-03-03 | 2001-09-12 | Gerd Schmitz | Method for the analysis of exogenic and endogenic cell activation based on measuring the aggregation of receptors |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| DK1353666T3 (da) | 2001-01-02 | 2013-10-14 | Cleveland Clinic Foundation | Myeloperoxidase, en risikoindikator for cardiovasculær sygdom |
| JP4062514B2 (ja) | 2001-01-02 | 2008-03-19 | ザ・クリーブランド・クリニック・ファンデーション | ミエロペルオキシダーゼ、心臓血管疾患についての危険性指示因子 |
| EP1358172B1 (en) * | 2001-01-10 | 2009-11-18 | The Regents of The University of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO2003005628A2 (en) | 2001-07-06 | 2003-01-16 | Lipomics Technologies, Inc. | Generating, viewing, interpreting, and utilizing a quantitative database of metabolites |
| JP2005500543A (ja) * | 2001-08-13 | 2005-01-06 | ビヨンド ジェノミクス， インコーポレイテッド | 生物学的系をプロファイリングするための方法およびシステム |
| US7262017B2 (en) | 2001-09-14 | 2007-08-28 | Torrey Pines Institute For Molecular Studies | Diagnostic markers for ischemia |
| WO2004038381A2 (en) | 2002-10-25 | 2004-05-06 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| EP1431399A1 (en) | 2002-12-20 | 2004-06-23 | Clinigenetics | Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| US20070148779A1 (en) * | 2003-03-28 | 2007-06-28 | Washington University In St. Louis | Multidimensional mass spectrometry or serum and celluar lipids directly from biologic extracts |
| US20070270350A1 (en) | 2003-12-23 | 2007-11-22 | Musc Foundation For Research Development | Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions |
| CN1897961A (zh) * | 2003-12-23 | 2007-01-17 | Musc研究发展基金会 | 预防和治疗炎性疾病或病症的方法和组合物 |
| JP2007530528A (ja) * | 2004-03-26 | 2007-11-01 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アテローム性動脈硬化症および脂質代謝異常の治療を目的としたセリンパルミトイルトランスフェラーゼ（ｓｐｔ）阻害剤の使用 |
| FI20041340A0 (fi) | 2004-10-15 | 2004-10-15 | Jurilab Ltd Oy | Menetelmä ja testipakkaus äkillisen sydäninfarktin riskin havaitsemiseksi |
| RU2428973C2 (ru) | 2005-03-03 | 2011-09-20 | Вайтал Хэлф Сайнсис Пти Лтд | Составы, обладающие липидопонижающими свойствами |
| EP1726962A1 (en) | 2005-05-24 | 2006-11-29 | Leiden University Medical Center | Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease |
| WO2007050318A2 (en) * | 2005-10-24 | 2007-05-03 | Duke University | Lipidomics approaches for central nervous system disorders |
| US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| WO2007127192A2 (en) * | 2006-04-24 | 2007-11-08 | Duke University | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| US8137977B2 (en) | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| CN101522910A (zh) | 2006-06-12 | 2009-09-02 | 佐拉生物科学有限公司 | 肌病的诊断方法 |
| EP2029771A4 (en) | 2006-06-12 | 2010-08-04 | Zora Biosciences Oy | DIAGNOSTIC METHOD OF MYOPATHY |
| DE102006034153B4 (de) | 2006-07-24 | 2018-02-08 | Magna powertrain gmbh & co kg | Getriebe |
| US8321154B2 (en) | 2007-03-26 | 2012-11-27 | Bg Medicine, Inc. | Methods for detecting coronary artery disease |
| US20100179066A1 (en) | 2007-06-07 | 2010-07-15 | Inserm (Institut National De La Santé Et De La Rec | Method for Assessing the Risk of a Cardiovascular Disease and for Diagnosing Dyslipidemia |
| US7847245B2 (en) * | 2007-07-18 | 2010-12-07 | Platomics, Inc. | Multiplexing matrix-analyte stereo electronic interactions for high throughput shotgun metabolomics |
| US8026099B2 (en) | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
| WO2009132082A2 (en) | 2008-04-22 | 2009-10-29 | Medical College Of Georgia Research Institute, Inc. | Immunogenic compositions containing ceramide and methods of use thereof |
| JP2010038858A (ja) * | 2008-08-08 | 2010-02-18 | Ikagaku:Kk | 動脈硬化に起因する疾患の発症を予知するために用いるキット |
| WO2010038104A1 (en) * | 2008-10-03 | 2010-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event. |
| US9110086B2 (en) | 2009-11-27 | 2015-08-18 | Baker Idi Heart And Diabetes Institute Holdings Limited | Lipid biomarkers for stable and unstable heart disease |
| ES2455124T5 (es) | 2010-05-05 | 2018-05-08 | Zora Biosciences Oy | Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca |
-
2011
- 2011-06-20 CN CN201180035877.9A patent/CN103154742B/zh active Active
- 2011-06-20 EP EP17184534.0A patent/EP3293522A3/en not_active Withdrawn
- 2011-06-20 US US13/805,319 patent/US9201080B2/en active Active
- 2011-06-20 CA CA2801459A patent/CA2801459C/en active Active
- 2011-06-20 CN CN201711362402.6A patent/CN108445241B/zh active Active
- 2011-06-20 EP EP11728229.3A patent/EP2583107A2/en not_active Withdrawn
- 2011-06-20 WO PCT/EP2011/060253 patent/WO2011161062A2/en not_active Ceased
- 2011-06-20 JP JP2013515841A patent/JP6262529B2/ja active Active
-
2015
- 2015-10-05 US US14/875,087 patent/US9841431B2/en active Active
-
2017
- 2017-03-07 JP JP2017042837A patent/JP6605521B2/ja active Active
- 2017-11-03 US US15/803,252 patent/US10261101B2/en active Active
-
2019
- 2019-03-04 US US16/291,845 patent/US10955427B2/en active Active
-
2021
- 2021-02-17 US US17/177,503 patent/US12270816B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532885A5 (enExample) | ||
| JP2014532886A5 (enExample) | ||
| JP2013527449A5 (enExample) | ||
| CA2798238A1 (en) | Lipidomic biomarkers for atherosclerosis and cardiovascular disease | |
| Yeang et al. | Effect of pelacarsen on lipoprotein (a) cholesterol and corrected low-density lipoprotein cholesterol | |
| Natesan et al. | Lipid metabolism, disorders and therapeutic drugs–review | |
| Karwatowska-Prokopczuk et al. | Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia | |
| Safarova et al. | Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond | |
| Silverman et al. | Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis | |
| Yahya et al. | Statin treatment increases lipoprotein (a) levels in subjects with low molecular weight apolipoprotein (a) phenotype | |
| Kalogirou et al. | Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia | |
| Sager et al. | Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients | |
| McKenney et al. | Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia | |
| Hartgers et al. | Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy | |
| Rosenson et al. | Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk | |
| Rudofsky et al. | Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe | |
| Bioletto et al. | Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects | |
| JP2015526696A5 (enExample) | ||
| Meeusen et al. | Lipid biomarkers for risk assessment in acute coronary syndromes | |
| Wadström et al. | Elevated remnant and LDL cholesterol and the risk of peripheral artery disease: a Mendelian randomization study | |
| Imhof et al. | Long-term prognostic value of IgM antibodies against phosphorylcholine for adverse cardiovascular events in patients with stable coronary heart disease | |
| EP3635411B1 (en) | Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in individual patients | |
| Glueck et al. | Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels> 500 mg/dl despite conventional triglyceride lowering therapy | |
| JP2016511407A5 (enExample) | ||
| Lacut et al. | Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? |